NCT05660993 2022-12-21Multicenter Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab, Bendamustine, Gemcitabine, Vinorelbine (Nivo-BeGEV) in Patients With Relapsed/Refractory Hodgkin LymphomaNational Research Center for Hematology, RussiaPhase 2 Unknown50 enrolled